Tel: 732-484-9848
Fax: 888-484-5008
Email: sales@chemscene.com
   
Buliding blocks
Intermediates
Bioactive molecules
Product Pathways
All Targets
Anti-infection
Antibody-drug conjugate....
Apoptosis
Cell Cycle/DNA Damage
GPCR/G protein
Immunology/Inflammation
JAK/STAT Signaling
MAPK/ERK Pathway
Membrane Transporter/Io....
Metabolism/Protease
Microbiology
Neuronal Signaling
NF-KB
Others
PI3K/Akt/mTOR
Protein Tyrosine Kinase....
TGF-beta/Smad
Vitamin D Related
Wnt/Hedgehog/Notch
Research Area
Cancer
Cardiovascular Disease
Endocrinology
Infection
Metabolic Disease
Neurological Disease
Others
Inflammation/Immunology
Product Type
All Products
New Products
Featured Products
Home   »   Product Pathways  »  PARP  »  BMN-673

Products are for research use only. Not for human use. We do not sell to patients.


CS-0937 BMN-673


(BMN673; BMN 673)
Structure Price and Availability of    BMN-673
United States
Size Price Stock
5mg $195 In-stock Inquiry
1g Get quote
5g Get quote
>10g Get quote
Inquiry for price and availability only. Please place your order via our email or fax.
Contact us for competitive discounts on bulk quantities .
  • Data Sheet
  • Introduction
  • References
  • Related Products

BMN-673  M.Wt: 380.35
BMN-673  Formula: C19H14F2N6O
BMN-673  Solubility: DMSO
BMN-673  Purity: >98%
BMN-673  Storage:  Please store the product under the recommended conditions in the Certificate of Analysis.
CAS: 1207456-01-6

View current batch:

BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development.

[1]. Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Abstract
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with advanced tumors with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalation phase in which the maximum tolerated dose will be defined, and a dose expansion phase.

[2]. Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Abstract
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.

[3]. PARP inhibitor BMN-673

PARP  |   PARP  |  
Keywords: buy BMN-673 | BMN-673 Supplier | purchase BMN-673 | BMN-673 cost | BMN-673 manufacturer | order BMN-673 | BMN-673 distributor | BMN-673 structure,chemscene
buy 1207456-01-6 | 1207456-01-6 Supplier | purchase 1207456-01-6 | 1207456-01-6 cost | 1207456-01-6 manufacturer | order 1207456-01-6 | 1207456-01-6 distributor | 1207456-01-6 structure,chemscene


CHEMSCENE, LLC
Tel: 732-484-9848
Fax: 888-484-5008
Email:  sales@chemscene.com
Address: 11 Deer Park Drive, Suite 102D Monmouth Junction, NJ 08852.
Products are for research use only. Not for human use. We do not sell to patients. Sitemap | Inhibitor © Copyright 2012. All Rights Reserved.